Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Alaunos Therapeutics ( (TCRT) ) has provided an announcement.
On July 16, 2025, Melinda Lackey informed Alaunos Therapeutics of her decision to terminate her consulting agreement, effective August 15, 2025. She will also resign from her roles as Legal and Administrative Officer and corporate secretary. Her departure is amicable and not due to any disagreements with the company’s operations, policies, or procedures. No additional severance arrangements were made beyond any accrued compensation owed to her.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Average Trading Volume: 39,069
Technical Sentiment Signal: Sell
Current Market Cap: $6.41M
See more data about TCRT stock on TipRanks’ Stock Analysis page.